Imatinib Mesylate
- Imatinib mesylate
- 220127-57-1
- Gleevec
- Glivec
- Imatinib mesilate
- Create:2005-03-26
- Modify:2025-01-18
- alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
- CGP 57148
- CGP-57148
- CGP57148
- CGP57148B
- Gleevec
- Glivec
- imatinib
- imatinib mesylate
- imatinib methanesulfonate
- Mesylate, Imatinib
- Methanesulfonate, Imatinib
- ST 1571
- ST1571
- STI 571
- STI-571
- STI571
- Imatinib mesylate
- 220127-57-1
- Gleevec
- Glivec
- Imatinib mesilate
- imatinib methanesulfonate
- Imatinib Mesylate (STI571)
- sti-571
- Imatinib accord
- Imatinib medac
- Imatinib (mesylate)
- imatinib monomesylate
- Shantinib
- Imatinib (as mesilate)
- NSC-716051
- QTI-571
- Imatinib methane sulfonate
- CGP 57148B
- Gleevec (Imatinib mesylate)
- QTI571
- STI 571
- DTXSID9040502
- CHEBI:31690
- HSDB 7142
- Imatinib Methansulfonate
- 8A1O1M485B
- 220127-57-1 (mesylate)
- MFCD04307699
- Imatinib mesylate [USAN]
- Imatinib monomethanesulfonate
- UNII-8A1O1M485B
- N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonate
- DTXCID7020502
- NSC716051
- NSC 716051
- 4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonate
- N-(4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonate
- Imatinib mesilate (JAN)
- Imatinib mesylate (USAN)
- Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)-, monomethanesulfonate
- IMATINIB MESILATE [JAN]
- IMATINIB MESILATE (MART.)
- IMATINIB MESILATE [MART.]
- CGP-57148B
- IMATINIB MESILATE (EP MONOGRAPH)
- IMATINIB MESILATE [EP MONOGRAPH]
- Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1)
- CAS-220127-57-1
- CGP-57148
- NCGC00159456-02
- 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate
- Genfatinib
- Gleevac
- Imatinib, methanesulfonate salt
- Imatinib mesylate?
- Mesylate, Imatinib
- 4-((4-methylpiperazin-1-yl)methyl)-N-(4-methyl-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)phenyl)benzamide methanesulfonate
- 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide methanesulfonate
- 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
- 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate
- 4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide methanesulfonate
- Gleevec (TN)
- Glivec (TN)
- Imatinib(free base)?
- ST-1571 Mesylate
- Imatinib mesylate400 mg
- Methanesulfonate, Imatinib
- SCHEMBL8217
- CHEMBL1642
- Benzamide,monomethanesulfonate
- Imatinib methanesulfonate salt
- MLS001401456
- C29H31N7O.CH4O3S
- Imatinib (Mesylate) (Standard)
- IMATINIB MESYLATE [HSDB]
- CGP57148B
- EX-A954
- IMATINIB MESYLATE [VANDF]
- YLMAHDNUQAMNNX-UHFFFAOYSA-N
- BCPP000204
- GGP-57148B
- HMS2052B09
- HMS2233D16
- HMS3265E01
- HMS3265E02
- HMS3265F01
- HMS3265F02
- HMS3372O12
- HMS3394B09
- HMS3654C07
- IMATINIB MESILATE [WHO-DD]
- BCP01255
- Tox21_111684
- AC-525
- HB1943
- HY-50946R
- s1026
- IMATINIB METHANESULFONATE [MI]
- AKOS015852497
- Tox21_111684_1
- BCP9000776
- CCG-101175
- IMATINIB MESYLATE [ORANGE BOOK]
- KS-1236
- NC00425
- NCGC00159456-11
- 111GE005
- BI164678
- HY-50946
- methanesulfonic acid; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
- methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
- SMR000469175
- SY013513
- I0936
- NS00076459
- SW197805-4
- D01441
- Imatinib Mesylate (CGP-57148B, STI-571)
- M06311
- A815828
- J-523068
- Q-201232
- Q27114666
- Imatinib Mesylate,Gleevec,Glivec,CGP-57148B,STI-571
- ST-1571 Mesylate , STI-571 , CGP-57148B
- ;4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
- 4-((4-Methyl-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)benzamide Monomethanesulfonate
- 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin- 3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamidemethanesulfonic acid salt
- 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)phenyl]benzamide methanesulfonic acid salt
- 4-[(4-Methyl-1-piperazinyl)-methyl]-N-{4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide monomethanesulphonate
- 4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate
- BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYL)METHYL)-N-(4-METHYL-3-((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINOPHENYL)-, METHANESULFONATE SALT
- BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYL)METHYL)-N-(4-METHYL-3-((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINOPHENYL)-, METHANESULPHONATE SALT
- hydron;methanesulfonate;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
- methanesulfonic acid; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide
- N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamidemethanesulfonate
247.638199 100
250.118195 68.82
248.139557 58.56
250.619278 17.39
262.108978 14.59
494.265717 100
394.165192 53.49
495.267822 46
395.169586 20.75
222.091766 9.26
Gleevec
Imkeldi
Imatinib mesylate is approved to treat:
• Acute lymphoblastic leukemia in adults and children that is Philadelphia chromosomepositive. In adults, it is used for cancer that has come back or does not respond to treatment. In children, it is used with chemotherapy as the first treatment after the cancer is diagnosed.
• Chronic eosinophilic leukemia or hypereosinophilic syndrome in adults.
• Chronic myelogenous leukemia that is Philadelphia chromosome positive. It is used in adults and children with:
• Newly-diagnosed chronic phase cancer.
• Chronic phase, accelerated phase, or blastic phase cancer that got worse after interferon-alpha therapy.
• Dermatofibrosarcoma protuberans in adults whose cancer has come back, has spread to other parts of the body, and/or cannot be removed by surgery.
• Gastrointestinal stromal tumor (GIST) that is KIT positive and cannot be removed by surgery and/or has spread to other parts of the body. It is also used after surgery to completely remove the tumor in adults with KIT-positive cancer.
• Myelodysplastic/myeloproliferative neoplasms in adults.
• Systemic mastocytosis that is aggressive and has a certain mutation in the c-KIT gene.
Imatinib mesylate is also being studied in the treatment of other conditions and types of cancer.
H302 (82.8%): Harmful if swallowed [Warning Acute toxicity, oral]
H351 (17.2%): Suspected of causing cancer [Warning Carcinogenicity]
H360 (13.8%): May damage fertility or the unborn child [Danger Reproductive toxicity]
P203, P264, P270, P280, P301+P317, P318, P330, P405, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)
Aggregated GHS information provided per 116 reports by companies from 18 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Reported as not meeting GHS hazard criteria per 1 of 116 reports by companies. For more detailed information, please visit ECHA C&L website.
There are 17 notifications provided by 115 of 116 reports by companies with hazard statement code(s).
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
Acute Tox. 4 (82.8%)
Carc. 2 (17.2%)
Repr. 1B (13.8%)
◉ Summary of Use during Lactation
Limited information indicates that maternal doses of imatinib up to 400 mg daily produce low levels of the drug and its active metabolite in milk. Although a few breastfed infants apparently experienced no adverse effects during maternal use of imatinib, no long-term data are available. Until more data are available, imatinib should be used only with careful monitoring during breastfeeding. National Comprehensive Cancer Network guidelines, the manufacturer and some authors recommend that breastfeeding be discontinued during imatinib therapy and for 1 month after therapy.
◉ Effects in Breastfed Infants
A woman receiving oral imatinib 400 mg daily for chronic myeloid leukemia breastfed her infant. No adverse effects were noted in the infant during the first 2 months of nursing.
One woman with chronic myelogenous leukemia received imatinib 400 mg daily throughout pregnancy and during breastfeeding (extent not stated) for nearly 6 months postpartum. Her infant reportedly grew and developed normally.
A woman with chronic myeloid leukemia received imatinib 400 mg daily starting at week 8 of pregnancy and continuing throughout 8 months of breastfeeding (extent not stated). The infant was healthy, but an atrial septal defect was repaired at 30 months of age. It was thought to be unrelated to imatinib therapy.
A pregnant woman with Philadelphia chromosome-positive chronic myelogenous leukemia was started on imatinib 400 mg daily during pregnancy. After delivery, her preterm infant was fed colostrum until the middle of the fifth day postpartum when exclusive formula feeding was instituted. The infant was treated for apnea of prematurity and discharged on day 25 of life. No adverse effects on growth or development were noted during the first year of life.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Patents are available for this chemical structure:
https://patentscope.wipo.int/search/en/result.jsf?inchikey=YLMAHDNUQAMNNX-UHFFFAOYSA-N
- CAS Common ChemistryLICENSEThe data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc/4.0/Imatinib mesylatehttps://commonchemistry.cas.org/detail?cas_rn=220127-57-1
- ChemIDplusImatinib mesylate [USAN]https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0220127571ChemIDplus Chemical Information Classificationhttps://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
- DTP/NCILICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuse
- EPA DSSToxImatinib mesylatehttps://comptox.epa.gov/dashboard/DTXSID9040502CompTox Chemicals Dashboard Chemical Listshttps://comptox.epa.gov/dashboard/chemical-lists/
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-notice4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonatehttps://echa.europa.eu/substance-information/-/substanceinfo/100.111.4374-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonate (EC: 606-892-3)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/254074-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide methanesulfonatehttps://echa.europa.eu/substance-information/-/substanceinfo/100.207.296
- FDA Global Substance Registration System (GSRS)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingImatinib Mesylatehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/8A1O1M485B
- Hazardous Substances Data Bank (HSDB)IMATINIB MESYLATEhttps://pubchem.ncbi.nlm.nih.gov/source/hsdb/7142
- ChEBIImatinib methanesulfonatehttps://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31690
- NCI Thesaurus (NCIt)LICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuseNCI Thesaurushttps://ncit.nci.nih.gov
- Open TargetsLICENSEDatasets generated by the Open Targets Platform are freely available for download.https://platform-docs.opentargets.org/licenceIMATINIB MESYLATEhttps://platform.opentargets.org/drug/CHEMBL1642
- ChEMBLLICENSEAccess to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).http://www.ebi.ac.uk/Information/termsofuse.htmlChEMBL Protein Target Treehttps://www.ebi.ac.uk/chembl/g/#browse/targets
- ClinicalTrials.govLICENSEThe ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
- DailyMed
- Drugs and Lactation Database (LactMed)
- Drugs@FDALICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- European Medicines Agency (EMA)LICENSEInformation on the European Medicines Agency's (EMA) website is subject to a disclaimer and copyright and limited reproduction notices.https://www.ema.europa.eu/en/about-us/legal-noticeGlivec (EMEA/H/C/000406)https://www.ema.europa.eu/en/medicines/human/EPAR/glivecImatinib Koanaa (EMEA/H/C/005595)https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-koanaaImatinib Accord (EMEA/H/C/002681)https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-accordImatinib medac (EMEA/H/C/002692)https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-medacImatinib Teva B.V. (EMEA/H/C/004748)https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-teva-bvimatinib mesilate (P/0028/2012)https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000463-pip01-08-m03imatinib mesilate (P/85/2011)https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000463-pip02-10
- EU Clinical Trials Register
- FDA Orange BookLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- KEGGLICENSEAcademic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial licensehttps://www.kegg.jp/kegg/legal.htmlTherapeutic category of drugs in Japanhttp://www.genome.jp/kegg-bin/get_htext?br08301.kegUSP drug classificationhttp://www.genome.jp/kegg-bin/get_htext?br08302.kegAnatomical Therapeutic Chemical (ATC) classificationhttp://www.genome.jp/kegg-bin/get_htext?br08303.kegTarget-based classification of drugshttp://www.genome.jp/kegg-bin/get_htext?br08310.keg
- MassBank of North America (MoNA)LICENSEThe content of the MoNA database is licensed under CC BY 4.0.https://mona.fiehnlab.ucdavis.edu/documentation/license
- National Drug Code (NDC) DirectoryLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- NCI Cancer DrugsGleevec (Imatinib Mesylate)https://www.cancer.gov/about-cancer/treatment/drugs/imatinibmesylate
- NLM RxNorm TerminologyLICENSEThe RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.htmlimatinib mesylatehttps://rxnav.nlm.nih.gov/id/rxnorm/284924
- Springer Nature
- Wikidataimatinib mesylatehttps://www.wikidata.org/wiki/Q27114666
- Wiley
- Medical Subject Headings (MeSH)LICENSEWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.https://www.nlm.nih.gov/copyright.htmlImatinib Mesylatehttps://www.ncbi.nlm.nih.gov/mesh/2009892Antineoplastic Agentshttps://www.ncbi.nlm.nih.gov/mesh/68000970Tyrosine Kinase Inhibitorshttps://www.ncbi.nlm.nih.gov/mesh/2103139
- PubChem
- GHS Classification (UNECE)GHS Classification Treehttp://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
- NORMAN Suspect List ExchangeLICENSEData: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0https://creativecommons.org/licenses/by/4.0/NORMAN Suspect List Exchange Classificationhttps://www.norman-network.com/nds/SLE/
- EPA Substance Registry ServicesEPA SRS List Classificationhttps://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do
- MolGenieMolGenie Organic Chemistry Ontologyhttps://github.com/MolGenie/ontology/
- PATENTSCOPE (WIPO)SID 389624226https://pubchem.ncbi.nlm.nih.gov/substance/389624226